Kayne Anderson Energy Infrastructure Fund Announces Distribution of $0.085 per Share for March 2026
HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- Kayne Anderson Energy Infrastructure Fund, Inc. (the “Company”) announced today a monthly distribution of $0.085 per share for March 2026. This distribution is payable to common stockholders on March 31, 2026 (as outlined in the table below).
The Company declares and pays distributions monthly. Payment of future distributions is subject to the approval of the Company’s Board of Directors, as well as meeting the covenants on the Company’s debt agreements and the terms of its preferred stock.
| Record Date / Ex-Date | Payment Date | Distribution Amount | Return of Capital Estimate |
|
| 3/13/26 | 3/31/26 | $0.085 | 50%
(
1
)
|
|
| (1) | This estimate is based on the Company’s anticipated earnings and profits. The final determination of the tax character of distributions will not be determinable until after the end of fiscal 2026 and may differ substantially from this preliminary information. |
Kayne Anderson Energy Infrastructure Fund, Inc. (NYSE: KYN) is a non-diversified, closed-end management investment company registered under the Investment Company Act of 1940, as amended, whose common stock is traded on the NYSE. The Company’s investment objective is to provide a high after-tax total return with an emphasis on making cash distributions to stockholders. KYN intends to achieve this objective by investing at least 80% of its total assets in securities of Energy Infrastructure Companies. See Glossary of Key Terms in the Company’s most recent quarterly or annual report for a description of these investment categories and the meaning of capitalized terms.
The Company pays cash distributions to common stockholders at a rate that may be adjusted from time to time. Distribution amounts are not guaranteed and may vary depending on a number of factors, including changes in portfolio holdings and market conditions.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Oncolytics Biotech Launches Randomized Colorectal Cancer Study

SAB BIO to Participate in Upcoming Investor Conferences



